Larimar Therapeutics, Inc. (LRMR) stock
LRMRNasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.02+0.32 (+11.85%)
Close on Nov 13, 2026Market cap $313.73MP/E –Yield –
Larimar Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Larimar Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $157.34M, up 73.7% year over year. For fiscal 2025 it was $154.22M, up 110.5% from the year before. Over ten years it grew 10.9% a year on average. The highest annual figure on record is $154.22M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $154.22M | +110.5% |
| FY2024 | Dec 31, 2024 | $73.28M | +164.8% |
| FY2023 | Dec 31, 2023 | $27.67M | +14.1% |
| FY2022 | Dec 31, 2022 | $24.25M | -36.8% |
| FY2021 | Dec 31, 2021 | $38.40M | +22.3% |
| FY2020 | Dec 31, 2020 | $31.41M | +51.1% |
| FY2019 | Dec 31, 2019 | $20.79M | -56.6% |
| FY2018 | Dec 31, 2018 | $47.93M | +17.4% |
| FY2017 | Dec 31, 2017 | $40.84M | +2.3% |
| FY2016 | Dec 31, 2016 | $39.94M | -26.9% |
| FY2015 | Dec 31, 2015 | $54.62M | +99.4% |
| FY2014 | Dec 31, 2014 | $27.39M | +186.5% |
| FY2013 | Dec 31, 2013 | $9.56M | -17.2% |
| FY2012 | Dec 31, 2012 | $11.54M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $28.00M | +19.8% |
| Q1 FY2026 | Mar 31, 2026 | $25.03M | -5.7% |
| Q4 FY2025 | Dec 31, 2025 | $59.37M | +122.1% |
| Q3 FY2025 | Sep 30, 2025 | $44.93M | +222.8% |
| Q2 FY2025 | Jun 30, 2025 | $23.37M | +18.7% |
| Q1 FY2025 | Mar 31, 2025 | $26.55M | +105.2% |
| Q4 FY2024 | Dec 31, 2024 | $26.74M | +151.1% |
| Q3 FY2024 | Sep 30, 2024 | $13.92M | +111.4% |
| Q2 FY2024 | Jun 30, 2024 | $19.68M | +235.0% |
| Q1 FY2024 | Mar 31, 2024 | $12.94M | +183.6% |
| Q4 FY2023 | Dec 31, 2023 | $10.65M | +47.5% |
| Q3 FY2023 | Sep 30, 2023 | $6.59M | +18.0% |
| Q2 FY2023 | Jun 30, 2023 | $5.88M | +4.1% |
| Q1 FY2023 | Mar 31, 2023 | $4.56M | -21.4% |
| Q4 FY2022 | Dec 31, 2022 | $7.22M | +14.7% |
| Q3 FY2022 | Sep 30, 2022 | $5.58M | -60.2% |
| Q2 FY2022 | Jun 30, 2022 | $5.64M | -38.0% |
| Q1 FY2022 | Mar 31, 2022 | $5.81M | -35.3% |
| Q4 FY2021 | Dec 31, 2021 | $6.29M | -40.5% |
| Q3 FY2021 | Sep 30, 2021 | $14.03M | +102.7% |
| Q2 FY2021 | Jun 30, 2021 | $9.10M | +2.2% |
| Q1 FY2021 | Mar 31, 2021 | $8.97M | +79.2% |
| Q4 FY2020 | Dec 31, 2020 | $10.57M | +95.6% |
| Q3 FY2020 | Sep 30, 2020 | $6.92M | -13.9% |
| Q2 FY2020 | Jun 30, 2020 | $8.91M | +184.8% |
| Q1 FY2020 | Mar 31, 2020 | $5.01M | -48.0% |
| Q4 FY2019 | Dec 31, 2019 | $5.41M | -52.8% |
| Q3 FY2019 | Sep 30, 2019 | $8.03M | -32.1% |
| Q2 FY2019 | Jun 30, 2019 | $3.13M | -74.4% |
| Q1 FY2019 | Mar 31, 2019 | $9.63M | -22.5% |
| Q4 FY2018 | Dec 31, 2018 | $11.46M | +5.0% |
| Q3 FY2018 | Sep 30, 2018 | $11.83M | +21.7% |
| Q2 FY2018 | Jun 30, 2018 | $12.21M | +16.0% |
| Q1 FY2018 | Mar 31, 2018 | $12.43M | +28.5% |
| Q4 FY2017 | Dec 31, 2017 | $10.91M | +50.0% |
| Q3 FY2017 | Sep 30, 2017 | $9.72M | -2.8% |
| Q2 FY2017 | Jun 30, 2017 | $10.53M | – |
| Q1 FY2017 | Mar 31, 2017 | $9.68M | – |
| Q4 FY2016 | Dec 31, 2016 | $7.28M | – |
| Q3 FY2016 | Sep 30, 2016 | $10.00M | – |
See a number that looks wrong?